Clinical Trial Update: Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability study of macitentan in patients with idiopathic pulmonary fibrosis was withdrawn. No results or ongoing enrollment are reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Macitentan (macitentan)

Snippet

Sponsor: Actelion | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: WITHDRAWN